Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q9)Sep 30, 2025 | (Q6)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 53.73%12.43B | 50.69%6.97B | 53.50%3.04B | 37.12%11.55B | 26.64%8.09B | 34.24%4.63B | 13.94%1.98B | 6.82%8.42B | 10.29%6.38B | -2.51%3.45B |
| Operating income | 53.73%12.43B | 50.69%6.97B | 53.50%3.04B | 37.12%11.55B | 26.64%8.09B | 34.24%4.63B | 13.94%1.98B | 6.82%8.42B | 10.29%6.38B | -2.51%3.45B |
| Cost of sales | ---- | -47.99%-3.92B | ---- | -39.09%-7.03B | ---- | -26.07%-2.65B | ---- | 3.37%-5.05B | ---- | 4.57%-2.1B |
| Operating expenses | -65.88%-7.4B | -47.99%-3.92B | -31.67%-1.51B | -39.09%-7.03B | -14.19%-4.46B | -26.07%-2.65B | -0.23%-1.15B | 3.37%-5.05B | -6.87%-3.91B | 4.57%-2.1B |
| Gross profit | 38.76%5.03B | 54.31%3.05B | 83.54%1.53B | 34.17%4.52B | 46.28%3.62B | 47.03%1.98B | 40.34%834.03M | 26.90%3.37B | 16.17%2.48B | 0.89%1.34B |
| Selling expenses | -3.64%-22.43M | -59.16%-25.62M | -6.48%-6.22M | -54.36%-48.47M | 8.37%-21.64M | -5.55%-16.09M | 26.36%-5.84M | 5.21%-31.4M | 55.48%-23.61M | 12.55%-15.25M |
| Administrative expenses | -10.92%-853.32M | -12.45%-699.94M | -29.52%-325.93M | -13.17%-1.47B | -12.30%-769.35M | -8.89%-622.46M | -8.44%-251.65M | 0.32%-1.3B | 24.63%-685.06M | 11.50%-571.64M |
| Research and development expenses | -8.45%-214.36M | ---- | 38.18%-37.91M | ---- | 7.79%-197.66M | ---- | -33.52%-61.32M | ---- | ---214.36M | ---- |
| Profit from asset sales | -120.24%-6.9K | ---- | ---6.28K | ---- | -27.43%34.12K | ---- | ---- | ---- | -3.97%47.01K | ---- |
| Revaluation surplus | 9,435.64%872.43M | ---- | -72.58%8.21M | ---- | 104.22%9.15M | ---- | 258.76%29.93M | ---- | 11.00%-216.7M | ---- |
| -Changes in the fair value of other assets | 9,435.64%872.43M | ---- | -72.58%8.21M | ---- | 104.22%9.15M | ---- | 258.76%29.93M | ---- | 11.00%-216.7M | ---- |
| Impairment and provision | -66.83%-716.93M | -53.10%-17.54M | 38.39%4.75M | 87.09%-19.51M | -410.76%-429.73M | 64.25%-11.46M | -69.87%3.43M | -47.77%-151.06M | -20.20%-84.14M | 41.43%-32.05M |
| -Other impairment is provision | -66.83%-716.93M | -53.10%-17.54M | 38.39%4.75M | 87.09%-19.51M | -410.76%-429.73M | 64.25%-11.46M | -69.87%3.43M | -47.77%-151.06M | -20.20%-84.14M | 41.43%-32.05M |
| Special items of operating profit | 239.11%161.05M | 262.07%183.1M | 187.78%16.08M | -42.32%-217.09M | 4.43%47.49M | -428.70%-112.98M | -252.68%-18.32M | -351.42%-152.53M | -81.98%45.48M | 286.91%34.37M |
| Operating profit | 94.12%3.88B | 105.19%2.49B | 130.93%1.08B | 59.43%2.76B | 79.56%2B | 59.72%1.21B | 73.65%468.47M | 35.95%1.73B | 22.32%1.11B | 140.64%759.84M |
| Financing cost | 19.26%-272.9M | 4.36%-252.69M | 15.13%-78.61M | 10.38%-544.59M | -5.16%-337.98M | 15.11%-264.21M | 18.14%-92.63M | -13.97%-607.69M | -7.46%-321.39M | ---311.24M |
| Share of profits of associates | ---- | 183.88%11.67M | ---- | 1,068.00%11.68M | ---- | 73.21%4.11M | ---- | 139.48%1M | ---- | -28.21%2.37M |
| Share of profit from joint venture company | ---- | 25.31%-357K | ---- | ---1.49M | ---- | ---478K | ---- | ---- | ---- | ---- |
| Adjustment items of earning before tax | 52.19%-32.2M | ---- | 17.48%-13.95M | ---- | -161.05%-67.36M | ---- | -3,542.43%-16.91M | ---- | -78.91%-25.8M | ---- |
| Earning before tax | 124.38%3.57B | 135.96%2.25B | 175.61%989.26M | 97.86%2.23B | 108.07%1.59B | 111.34%953.08M | 128.46%358.93M | 52.40%1.13B | 28.42%764.91M | 41.46%450.98M |
| Tax | -116.90%-786.59M | -108.32%-472.18M | -98.25%-159.07M | -31.05%-377.56M | -59.88%-362.65M | -164.74%-226.66M | -66.15%-80.24M | -60.94%-288.11M | -25.41%-226.82M | 21.44%-85.62M |
| After-tax profit from continuing operations | 126.59%2.78B | 144.58%1.78B | 197.88%830.19M | 120.81%1.85B | 128.39%1.23B | 98.82%726.42M | 156.11%278.7M | 49.67%838.42M | 29.73%538.09M | 74.13%365.36M |
| Earning after tax | 126.59%2.78B | 144.58%1.78B | 197.88%830.19M | 120.81%1.85B | 128.39%1.23B | 98.82%726.42M | 156.11%278.7M | 49.67%838.42M | 29.73%538.09M | 74.13%365.36M |
| Minority profit | 91.60%667.34M | 94.10%337M | 198.35%171.01M | 163.53%400.53M | 101.58%348.29M | 54.33%173.63M | 466.16%57.32M | -3.95%151.99M | 15.60%172.78M | 10.26%112.5M |
| Profit attributable to shareholders | 140.43%2.12B | 160.44%1.44B | 197.76%659.18M | 111.35%1.45B | 141.07%880.64M | 118.62%552.79M | 124.30%221.38M | 70.77%686.43M | 37.69%365.31M | 134.61%252.86M |
| Basic earnings per share | 111.54%0.55 | 216.67%0.38 | 240.00%0.17 | 150.00%0.35 | 136.36%0.26 | 200.00%0.12 | 66.67%0.05 | 100.00%0.14 | 37.50%0.11 | 33.33%0.04 |
| Diluted earnings per share | 216.67%0.38 | 150.00%0.35 | 200.00%0.12 | 100.00%0.14 | 33.33%0.04 | |||||
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | HKAS | CAS (2007) | HKAS | CAS (2007) | HKAS | CAS (2007) | HKAS | CAS (2007) | HKAS |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- | -- |
| Auditor | -- | -- | -- | Ernst & Young | -- | -- | -- | Ernst & Young | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.